368 related articles for article (PubMed ID: 34523813)
21. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
22. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
24. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
25. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
26. Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients.
Brakta C; Stépanian A; Reiner P; Delrue M; Mazighi M; Curis E; Siguret V
J Stroke; 2023 Jan; 25(1):126-131. PubMed ID: 36592965
[TBL] [Abstract][Full Text] [Related]
27. Quick reference guide to apixaban.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
[TBL] [Abstract][Full Text] [Related]
28. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
Becker RC; Yang H; Barrett Y; Mohan P; Wang J; Wallentin L; Alexander JH
J Thromb Thrombolysis; 2011 Aug; 32(2):183-7. PubMed ID: 21516308
[TBL] [Abstract][Full Text] [Related]
29. Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
Hakeam HA; Alkhani M; Alyahya Z; Alawaji Z; Ofori S
J Cardiovasc Pharmacol; 2021 Dec; 78(6):867-874. PubMed ID: 34882113
[TBL] [Abstract][Full Text] [Related]
30. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
[TBL] [Abstract][Full Text] [Related]
31. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.
Ząbczyk M; Natorska J; Kopytek M; Malinowski KP; Undas A
Arch Pathol Lab Med; 2021 Jan; 145(1):99-104. PubMed ID: 33367661
[TBL] [Abstract][Full Text] [Related]
34. Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation.
Schapkaitz E; Ter Morshuizen B; Mc Cree M; F Jacobson B
Clin Appl Thromb Hemost; 2024; 30():10760296241249167. PubMed ID: 38659339
[TBL] [Abstract][Full Text] [Related]
35. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
[TBL] [Abstract][Full Text] [Related]
36. Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study.
Pailleret C; Jourdi G; Siguret V; Gouin-Thibault I; Gandrille S; Stepanian A; Curis E; Golmard JL; Gaussem P; Le Bonniec B; Samama CM
Eur J Anaesthesiol; 2019 Jun; 36(6):449-456. PubMed ID: 30308522
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
[TBL] [Abstract][Full Text] [Related]
38. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
40. The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.
Brendel LC; Dobler F; Hessling G; Michel J; Braun SL; Steinsiek AL; Groha P; Eckl R; Deisenhofer I; Hyseni A; Roest M; Ott I; Steppich B
J Interv Card Electrophysiol; 2017 Sep; 49(3):237-244. PubMed ID: 28735423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]